TLSI — TriSalus Life Sciences, Inc.

Summary of TriSalus Life Sciences Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $13.2 million, a 60% increase year-over-year from $8.3 million.
• Full Year Revenue: $45.2 million, a 53% increase compared to the previous year.
• Gross Margin: 87% for Q4, up from 85% in the prior year.
• Net Operating Loss: $3.3 million for Q4, improved from $7.6 million in Q4 2024.
• Adjusted EBITDA Loss: Approximately $950,000 for Q4, significantly better than an adjusted EBITDA loss of $5.7 million in Q4 2024.
• Cash Position: $20.4 million as of December 31, 2025, bolstered by a $46 million public offering in February 2026.

2. Strategic Updates and Business Highlights

• Product Expansion: The TriNav product suite expanded from 2 to 7 offerings, enhancing the company’s market position in embolization procedures.
• New Product Launches: Key products launched include TriNav LV, TriGuide, TriNav FLX, and TriNav XP, with TriNav Advance expected in H1 2026.
• Clinical Studies: Significant investments in foundational clinical studies to validate the PEDD platform, with promising results from ongoing trials in thyroid and knee osteoarthritis treatments.
• Board Strengthening: Appointment of Michael Stansky to the Board, enhancing governance and strategic oversight.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected revenue in the range of $60 million to $62 million, with growth weighted towards the second half of the year.
• Sales Strategy: Plans to double the sales force to enhance market penetration and productivity, with a focus on onboarding and training.
• Market Opportunities: Continued emphasis on liver embolization while also targeting new applications in thyroid and uterine artery embolization.

4. Bad News, Challenges, or Points of Concern

• Delayed Clinical Data: The anticipated update on the nelitolimod program was postponed to H2 2026 to consolidate data from multiple studies, which may raise concerns about the program's timeline.
• Increased Expenses: Sales and marketing expenses rose to $8 million in Q4, reflecting higher performance-based compensation, which could impact profitability.
• Operating Losses: Despite improvements, the company reported significant operating losses for both the quarter and the year, indicating ongoing financial challenges.

5. Notable Q&A Insights

• Growth Contributions: Management indicated that liver-related products will continue to dominate revenue, but they expect meaningful contributions from new applications in the second half of 2026.
• Sales Organization Structure: Plans to significantly enhance the sales organization with a focus on pairing clinical specialists with sales representatives to improve physician engagement.
• Mapping Growth: The introduction of new products like TriNav XP and Advance is expected to drive growth in mapping and simulation procedures, with confidence in the ongoing adoption of the TriNav platform across various applications.
• Long-term Market Potential: Management expressed optimism about the long-term growth potential in both liver and non-liver markets, driven by clinical data and physician adoption.

Overall, TriSalus Life Sciences demonstrated strong financial performance in Q4 2025, with a clear strategy for growth and product expansion, despite some challenges related to clinical data timelines and ongoing operating losses.